Brief: Neoleukin Therapeutics Announces Restructuring And Leadership Transition

Neurogene

08/03/2023 22:02

March 8 (Reuters) - Neoleukin Therapeutics Inc  NLTX.O :
    * NEOLEUKIN THERAPEUTICS PROVIDES STRATEGIC UPDATE AND
ANNOUNCES
RESTRUCTURING AND LEADERSHIP TRANSITION
    * NEOLEUKIN THERAPEUTICS INC - ENGAGED SVB SECURITIES TO
ASSIST IN
REVIEWING STRATEGIC ALTERNATIVES FOR COMPANY
    * NEOLEUKIN THERAPEUTICS INC - ALTERNATIVES MAY INCLUDE A
SALE,
MERGER, DIVESTITURE OF ASSETS, LICENSING OR OTHER STRATEGIC
TRANSACTION
    * NEOLEUKIN THERAPEUTICS INC - REDUCTION IN CO'S WORKFORCE
BY
ABOUT 70%
    * NEOLEUKIN THERAPEUTICS INC - BOARD OF DIRECTORS OF
NEOLEUKIN
ALSO APPROVED A FURTHER CORPORATE RESTRUCTURING TO PRESERVE CASH
    * NEOLEUKIN THERAPEUTICS INC - CHIEF EXECUTIVE OFFICER
JONATHAN
DRACHMAN, M.D., WILL ALSO BE STEPPING DOWN AFTER A SHORT
TRANSITION
    * NEOLEUKIN THERAPEUTICS INC - EXPECTS REDUCTION IN FORCE TO
BE
COMPLETED DURING FIRST HALF OF 2023

Source text for Eikon:  ID:nGNX2TKzyl 
Further company coverage:  NLTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))